In this study we discovered, through screening of a mechanistically defined library, that BRAFi resistance in melanoma cell lines is accompanied by increased sensitivity to a broad class of mitotic disrupters, including AURK, PLK, tubulin, and kinesin inhibitors or, in the one resistant line, to Chk1/2 inhibitors. Here, CHEK1 is linked to melanoma.